LOGIN  |  REGISTER
Terns Pharmaceuticals

electroCore to Participate in Upcoming Investor Conferences

July 22, 2025 | Last Trade: US$4.98 0.08 1.63

ROCKAWAY, N.J., July 22, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the following investor conferences.

  • Needham 10th Annual Virtual MedTech and Diagnostics Conference, taking place virtually on Monday, August 11 and Tuesday, August 12, 2025. Management will host will host one-on-one meetings throughout both days.
  • Canaccord Genuity 45th Annual Growth Conference, taking place in Massachusetts on Tuesday, August 12 and Wednesday, August 13, 2025 at the InterContinental in Boston. Management will be presenting on Tuesday, August 12 at 3:30 p.m. ET and will host one-on-one meetings throughout both days.

Investors who wish to request a meeting should contact their sales representative at the sponsoring firms or reach out the electroCore Investor Relations at This email address is being protected from spambots. You need JavaScript enabled to view it..

About electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products to treat chronic pain syndromes through non-invasive neuromodulation technology are gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator. Additionally, the company commercializes its Truvaga products, handheld, and personal use nVNS products utilizing bioelectronic technologies, to promote general wellness and human performance.

For more information, visit www.electrocore.com.

Contact

ECOR Investor Relations
(973) 302-9253
This email address is being protected from spambots. You need JavaScript enabled to view it.

C4 Therapeutics

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page